Gouty Arthritis (Gout) - Pipeline Review, H1 2012

Gouty Arthritis (Gout) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Gouty Arthritis (Gout) - Pipeline Review, H1 2012', provides an overview of the Gouty Arthritis (Gout) therapeutic pipeline. This report provides information on the therapeutic development for Gouty Arthritis (Gout), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout). 'Gouty Arthritis (Gout) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gouty Arthritis (Gout).
- A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gouty Arthritis (Gout) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Gouty Arthritis (Gout) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Gouty Arthritis (Gout) Therapeutic Products under Development, Key Players in Gouty Arthritis (Gout) Therapeutics, Gouty Arthritis (Gout) Pipeline Overview, Gouty Arthritis (Gout) Pipeline, Gouty Arthritis (Gout) Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gouty Arthritis (Gout) Overview
Therapeutics Development
An Overview of Pipeline Products for Gouty Arthritis (Gout)
Gouty Arthritis (Gout) Therapeutics under Development by Companies
Gouty Arthritis (Gout) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Gouty Arthritis (Gout) Therapeutics – Products under Development by Companies
Gouty Arthritis (Gout) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Gouty Arthritis (Gout) Therapeutics Development
Novartis AG
Savient Pharmaceuticals, Inc.
Ardea Biosciences, Inc.
BioCryst Pharmaceuticals, Inc.
SANWA KAGAKU KENKYUSHO CO.,LTD.
Regeneron Pharmaceuticals, Inc.
LG Life Sciences, Ltd
Metabolex, Inc
Wellstat Therapeutics Corporation
Opsona Therapeutics Ltd.
PLx Pharma Inc.
Nuon Therapeutics, Inc.
Polaris Group
Gouty Arthritis (Gout) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RDEA594 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDEA684 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ilaris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PNXXXX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCX4208 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arcalyst - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Krystexxa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL 4100 Indomethacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NU1618 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegsitacase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDEA594 + Allopurinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDEA594 + Febuxostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCX4208 + Allopurinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoledronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NanoActive Indomethacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LC350189 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Inflammasome Modulator Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XO Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Next Generation URAT1 Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDEA3170 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SK-0910 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gouty Arthritis (Gout) Therapeutics – Drug Profile Updates
Gouty Arthritis (Gout) Therapeutics – Discontinued Products
Gouty Arthritis (Gout) – Product Development Milestones
Featured News & Press Releases
Jan 08, 2012: BioCryst Announces Positive Results From Ongoing BCX4208 Phase IIb Study In Patients With Gout
Jan 06, 2012: Centers For Medicare And Medicaid Services Assign Permanent J-Code To Savient Pharmaceuticals's KRYSTEXXA
Jan 05, 2012: Phase II Clinical Trial Of Rilonacept Shows Significant Reduction Of Gout Flares
Dec 19, 2011: Ardea Biosciences Initiates Phase III Clinical Development Program For Lesinurad
Nov 22, 2011: Regeneron Announces FDA Acceptance Of ARCALYST Supplemental Biologics License Application For Review
Nov 08, 2011: BioCryst Pharmaceuticals Presents New BCX4208 Gout Data At 2011 ACR/ARHP Annual Scientific Meeting
Nov 07, 2011: Ardea Biosciences Presents Initial Clinical Results For RDEA3170 At 2011 ACR/ARHP Annual Scientific Meeting
Nov 07, 2011: Ardea Provides Additional Positive Results For Phase IIb Study Of Lesinurad/Allopurinol Combination At 2011 ACR/ARHP Annual Scientific Meeting
Nov 05, 2011: Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA And Impact Of Refractory Chronic Gout At American College Of Rheumatology Meeting
Nov 03, 2011: Savient Pharmaceuticals Receives J-Code For KRYSTEXXA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Gouty Arthritis (Gout), H1 2012
Products under Development for Gouty Arthritis (Gout) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Novartis AG, H1 2012
Savient Pharmaceuticals, Inc., H1 2012
Ardea Biosciences, Inc., H1 2012
BioCryst Pharmaceuticals, Inc., H1 2012
SANWA KAGAKU KENKYUSHO CO.,LTD., H1 2012
Regeneron Pharmaceuticals, Inc., H1 2012
LG Life Sciences, Ltd, H1 2012
Metabolex, Inc, H1 2012
Wellstat Therapeutics Corporation, H1 2012
Opsona Therapeutics Ltd., H1 2012
PLx Pharma Inc., H1 2012
Nuon Therapeutics, Inc., H1 2012
Polaris Group, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Gouty Arthritis (Gout) Therapeutics – Drug Profile Updates
Gouty Arthritis (Gout) Therapeutics – Discontinued Products

List of Figures
Number of Products under Development for Gouty Arthritis (Gout), H1 2012
Products under Development for Gouty Arthritis (Gout) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012